PAMU
NBIX icon

Pictet Asset Management (UK)’s Neurocrine Biosciences NBIX Stock Holding History

Pictet Asset Management (UK)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$168M Buy
1,722,709
+160,186
+10% +$15.4M 0.18% 164
2021
Q1 		$152M Sell
1,562,523
-134,467
-8% -$14.1M 0.18% 156
2020
Q4 		$163M Buy
1,696,990
+366,467
+28% +$35.4M 0.21% 136
2020
Q3 		$128M Buy
1,330,523
+23,769
+2% +$2.75M 0.2% 150
2020
Q2 		$159M Buy
1,306,754
+402,559
+45% +$44.5M 0.27% 111
2020
Q1 		$78.3M Buy
904,195
+48,441
+6% +$4.74M 0.17% 163
2019
Q4 		$92M Sell
855,754
-185,246
-18% -$19.4M 0.16% 168
2019
Q3 		$93.8M Buy
1,041,000
+91,310
+10% +$8.53M 0.2% 142
2019
Q2 		$80.2M Sell
949,690
-29,518
-3% -$2.42M 0.17% 157
2019
Q1 		$86.3M Buy
979,208
+39,729
+4% +$3.32M 0.19% 156
2018
Q4 		$67.1K Buy
939,479
+61,486
+7% +$5.89M 0.17% 171
2018
Q3 		$108M Sell
877,993
-38,536
-4% -$4.37M 0.23% 135
2018
Q2 		$90M Sell
916,529
-23,342
-2% -$2.09M 0.22% 144
2018
Q1 		$77.9M Sell
939,871
-180,790
-16% -$15.3M 0.19% 160
2017
Q4 		$87M Sell
1,120,661
-225,194
-17% -$15.4M 0.22% 142
2017
Q3 		$82.5M Buy
1,345,855
+204,996
+18% +$10.8M 0.23% 133
2017
Q2 		$49.6M Buy
1,140,859
+124,965
+12% +$6.06M 0.15% 183
2017
Q1 		$44M Buy
1,015,894
+234,157
+30% +$10M 0.14% 195
2016
Q4 		$30.3M Buy
781,737
+85,359
+12% +$3.86M 0.11% 238
2016
Q3 		$35.3M Sell
696,378
-8,851
-1% -$441K 0.13% 212
2016
Q2 		$35M Buy
705,229
+513,172
+267% +$23.6M 0.14% 202
2016
Q1 		$7.06M Buy
192,057
+40,303
+27% +$1.6M 0.03% 460
2015
Q4 		$8.59M Buy
151,754
+124,254
+452% +$6.32M 0.04% 436
2015
Q3 		$1.09M Buy
+27,500
New +$1.33M ﹤0.01% 775

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pictet Asset Management (UK)'s NBIX Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Neurocrine Biosciences (NBIX) stake by 10% in Q2 2021, buying an estimated $15.4M and bringing the position to 1,722,709 shares worth $168M. The position accounts for 0.18% of the portfolio, ranked #164.

Pictet Asset Management (UK) first reported a position in NBIX in Q3 2015 and has held it in 24 quarters since. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Pictet Asset Management (UK) held 1,722,709 shares of Neurocrine Biosciences worth $168M as of Q2 2021.
  • Pictet Asset Management (UK) bought 160,186 Neurocrine Biosciences shares in Q2 2021, an estimated $15.4M.
  • Neurocrine Biosciences made up 0.18% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #164 holding.
  • Pictet Asset Management (UK) first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 24 quarters since.
  • 408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.